Europe Chronic Idiopathic Constipation Drug Market Forecast 2017-2025

Publisher Name :
Date: 24-Sep-2017
No. of pages: 65

Key Findings

The Europe chronic idiopathic constipation drug market is estimated to grow at a CAGR of 8.80% during the forecast years of 2017-2025.The market value is estimated to increase from $1283 million in 2016 and reach $2721 million by 2025.

Market Insights

The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries. The market can be segmented into two types on the basis of the type of prescriptions and the type of drugs. The type of prescriptions can be further divided into over the counter drugs and the doctor prescribed ones. The drug types are mainly subdivided into linaclotide and lubiprostone. Lubiprostone is the leading drug in the market.

Competitive Insights

The top players in the market include Progenics Pharmaceuticals Inc, Theravance Biopharma Inc, Cosmo Pharmaceuticals Sa, Valeant Pharmaceuticals International, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc,Eli Lilly And Company, Bayer Ag, Merck Sharp & Dohme,Roche Holding Ag, Pfizer, GlaxoSmithKline,Synergy Pharmaceuticals, Chugai Pharmaceutical, Allergens and Ferring International Center S.A.

Europe Chronic Idiopathic Constipation Drug Market Forecast 2017-2025

Table of Contents

1. Research Scope
1.1. Study Goals
1.2. Scope of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study and Forecasting Years
2. Research Methodology
2.1. Sources of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-Up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
4. Market Overview
4.1. Market Definition
4.2. Key Market Insights
4.3. Attractive Investment Scenario
4.4. Positioning of Key Cic Drugs Manufacturers In The Market
4.5. Market Drivers
4.5.1. Modern Dietary Habits Taking Toll On The Health
4.5.2. Cancer Or Other Systematic Disease Can Lead To Cic
4.5.3. Increasing Elderly Population
4.5.4. Improved and Efficient Drugs In Pipeline
4.5.5. Increasing Constipation Problems Due To Side Effects of Prescribed Medicines
4.6. Restraints
4.6.1. Surgical Treatments
4.6.2. Unawareness and Ignorance Among People
4.7. Opportunities
4.7.1. High Unmet Needs
4.8. Challenges
4.8.1. Side Effects of Cic Drugs
5. Europe Cic Drugs Market, By Drug Type 2017-2025 ($ Million)
5.1. Overview
5.1.1. Lubiprostone
5.1.2. Linaclotide
5.1.3. Others
5.2. Pipeline Drug Analysis: Phase 3: Plecanatide (Year of Launch 2022, $ Million)
5.3. Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch 2022, $ Million)
6. Europe Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
6.1. Prescribed Drugs
6.2. Over The Counter Drugs
7. Key Analytics
7.1. Porters Five Force Analysis
7.1.1. Intensity of Competitive Rivalry
7.1.2. Bargaining Power of Suppliers
7.1.3. Bargaining Power of Buyers
7.1.4. Threat of Substitute Products
7.1.5. Threat of New Entrants
7.2. Vendor Landscape
7.3. Opportunity Matrix
8. Europe Cic Drugs Market By Countries 2017-2025 ($ Million)
8.1. Uk
8.2. Germany
8.3. Rest of Europe
9. Company Profiles
9.1. Allergens
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Strategic Moves
9.1.4. Scot Analysis
9.2. Chugai Pharmaceutical
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Strategic Moves
9.2.4. Scot Analysis
9.3. Ferring International Center S.A.
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Scot Analysis
9.4. Synergy Pharmaceuticals
9.4.1. Overview
9.4.2. Product Portfolio
9.4.3. Scot Analysis
9.5. Pfizer
9.5.1. Overview
9.5.2. Pfizer Product Portfolio
9.5.3. Scot Analysis
9.6. Glaxosmithkline
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Scot Analysis
9.7. Roche Holding Ag
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Strategic Moves
9.7.4. Scot Analysis
9.8. Sanofi
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Scot Analysis
9.9. Bayer Ag
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.10. Merck Sharp & Dohme
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Scot Analysis
9.11. Eli Lilly and Company
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Scot Analysis
9.12. Salix Pharmaceuticals Ltd
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Scot Analysis
9.13. Sucampo Pharmaceuticals Inc
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Scot Analysis
9.14. Ironwood Pharmaceuticals Inc
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Scot Analysis
9.15. Valeant Pharmaceuticals International
9.15.1. Overview
9.16. Daiichi Sankyo Co Ltd
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Scot Analysis
9.17. Cosmo Pharmaceuticals Sa
9.17.1. Overview
9.17.2. Product Portfolio
9.17.3. Scot Analysis
9.18. Progenics Pharmaceuticals Inc
9.18.1. Overview
9.18.2. Product Portfolio
9.18.3. Scot Analysis
9.19. Theravance Biopharma Inc
9.19.1. Overview
9.19.2. Product Portfolio
9.19.3. Scot Analysis

List of Tables
Table 1 Europe Cic Drug Market By Countries 2017-2025 ($ Million)
Table 2 Prominent Drugs and Their Respective Companies In Therapeutics For Chronic Constipation
Table 3 Constipation In Parkinson's Disease
Table 4 Common Medicines Causing Constipation
Table 5 Europe Cic Drugs Market By Drug Type 2014-2022($ Million)
Table 6 Product Profile (Lubiprostone)
Table 7 Product Profile (Linaclotide)
Table 8 Product Profile (Bisacodyl)
Table 9 Pipeline Product Profile (Plecanatide)
Table 10 Pipeline Product Profile (Elobixibat)
Table 11 Europe Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
Table 12 Linzess Precautions and Side Effects
Table 13 Europe Cic Drugs Market By Country 2017-2025 ($ Million)
Table 14 Uk Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
Table 15 Uk Cic Drugs Market By Major Drugs 2017-2025 ($ Million)
Table 16 Germany Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
Table 17 Germany Cic Drugs Market By Major Drugs 2017-2025 ($ Million)

List of Figures
Figure 1 Europe Chronic Idiopathic Constipation (Cic) Drug Market 2017-2025 ($ Million)
Figure 2 Europe Cic Drug Market By Drug Type 2017-2025 ($ Million)
Figure 3 Europe Cic Drug Market By Prescription Type In 2016 ($ Million)
Figure 4 Causes of Constipation
Figure 5 Proportion of Population Aged 60 Or Above In 2014
Figure 6 Major Causes of Constipation In Elderly People
Figure 7 Effective Drugs To Create Huge Market Benefits
Figure 8 Surgical Options Available For Constipation
Figure 9 Need of Surgery Process
Figure 10 Common Constipation Drugs and Side Effects Caused Due To Them
Figure 11 Europe Lubiprostone Drug Market 2017-2025 ($ Million)
Figure 12 Europe Linaclotide Drug Market 2017-2025 ($ Million)
Figure 13 Europe Other Drugs Market 2017-2025 ($ Million)
Figure 14 Europe Prescribed Cic Drugs Market 2017-2025 ($ Million)
Figure 15 Europe Over The Counter Cic Drug Market 2017-2025 ($ Million)
Figure 16 Europe Cic Drugs Market 2017-2025 ($ Million)
Figure 17 Uk Cic Drug Market 2017-2025 ($ Million)
Figure 18 Germany Cic Drug Market, 2017-2025 $ Million)
Figure 19 Rest of Europe Cic Drug Market 2017-2025 ($ Million)
  • Global Esomeprazole Market Research Report 2018
    Published: 13-Jul-2018        Price: US 2900 Onwards        Pages: 93
    This report studies the global Esomeprazole market status and forecast, categorizes the global Esomeprazole market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Esomeprazole market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major man......
  • 2018-2023 Global Gastrointestinal Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 164
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Gastrointestinal market for 2018-2023. Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gast......
  • 2018 Top 5 Gastrointestinal Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Jul-2018        Price: US 4960 Onwards        Pages: 145
    Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gastrointestinal is in a slight decreasing trend, and the gross margin is 63% in 2015. Europe region is the largest supplier of Gastrointestinal, with a production revenue marke......
  • Hepatic Encephalopathy - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 72
    Hepatic Encephalopathy - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, dro......
  • Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 35
    Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape. Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called func......
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 91
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2018, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape. Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. T......
  • Colitis - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 108
    Colitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2018, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory ......
  • Primary Sclerosing Cholangitis - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 111
    Primary Sclerosing Cholangitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the......
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 83
    Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2018, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape. When the liquid content of the stomach refluxes into the esophagus, that condition is called Gastro esophageal reflux disease (GERD). It is a chronic condi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs